TY - JOUR
T1 - Cognitive therapy augmentation versus CT switch treatment
T2 - A Star*D report
AU - Friedman, Edward S.
AU - Thase, Michael E.
AU - Wisniewski, Stephen R.
AU - Trivedi, Madhukar H.
AU - Biggs, Melanie M.
AU - Fava, Maurizio
AU - Warden, Diane
AU - Niederehe, George
AU - Luther, James F.
AU - Rush, A. John
N1 - Funding Information:
This project has been funded with Federal funds from the National Institute of Mental Health, National Institutes of Health, under Contract N01MH90003 to UT Southwestern Medical Center at Dallas (P.I.: A.J. Rush). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. We appreciate the support of Bristol-Myers Squibb Company, Forest Pharmaceuticals Inc., GlaxoSmithKline, King Pharmaceuticals, Organon Inc., Pfizer Inc., and Wyeth-Ayerst Laboratories for providing medications at no cost for this trial. We would like to acknowledge the editorial support of Jon Kilner, MS, MA, and the secretarial support of Fast Word Information Processing, Inc. (Dallas, Texas).
Funding Information:
This project has been funded with Federal funds from the National Institute of Mental Health, National Institutes of Health, under Contract N01MH90003 to UT Southwestern Medical Center at Dallas (P.I.: A.J. Rush). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Funding Information:
We appreciate the support of Bristol-Myers Squibb Company, Forest Pharmaceuticals Inc., GlaxoSmithKline, King Pharmaceuticals, Organon Inc., Pfizer Inc., and Wyeth-Ayerst Laboratories for providing medications at no cost for this trial. We would like to acknowledge the editorial support of Jon Kilner, MS, MA, and the secretarial support of Fast Word Information Processing, Inc. (Dallas, Texas).
Funding Information:
Dr. Rush has provided scientific consultation to or served on Advisory Boards for Advanced Neu-ronetic Systems, Inc., AstraZeneca, Best Practice Project Management, Inc., Bristol-Myers Squibb Company, Cyberonics Inc., Eli Lilly & Company, Forest Pharmaceuticals, Inc., Gerson Lehman Group, GlaxoSmithKline, Jazz Pharmaceuticals, Magellan Health Services, Merck Co., Inc., Neu-ronetics, Ono Pharmaceutical, Organon, Inc., PamLab, Personality Disorder Research Corp., Pfizer, Inc., The Urban Institute, and Wyeth-Ayerst Laboratories, Inc. He has received royalties from Guil-ford Publications and Healthcare Technology Systems, Inc. and research/grant support from the Robert Wood Johnson Foundation, the National Institute of Mental Health, and the Stanley Foundation. He has been on speaker bureaus for Cyberonics, Inc., Forest Pharmaceuticals, Inc., GlaxoSmithKline, and Eli Lilly & Company; and owns stock in Pfizer, Inc.
Publisher Copyright:
© 2009 International Association for Cognitive Psychotherapy.
PY - 2009
Y1 - 2009
N2 - Objective: This report compares the effectiveness of cognitive therapy (CT) as an augmentation to citalopram vs. CT as a switch from citalopram as a second-step treatment for outpatients with non-psychotic major depressive disorder (MDD) who had received unsatisfactory benefit from an initial trial of citalopram. Methods: Participants who experienced intolerance to or who did not reach remission with an optimal trial of citalopram, and who accepted randomization only to one of the two CT options, were randomized to a second-step treatment of either CT switch or CT augmentation of citalopram. Treatment outcomes, side effects, and serious adverse events were compared between the two groups. Results: As a second-step treatment following an optimal trial of citalopram, discontinuing medication and switching to CT (n=32) was as effective as augmenting citalopram with CT (n=26). Unlike the CT switch subjects, most individuals in the CT augmentation group endorsed mild-to-marked levels of side effect frequency, intensity, and burden. Conclusions: This is the first study to compare CT as a switch or augmentation strategy following unsatisfactory benefit or intolerance to an SSRI antidepressant medication. In these individuals with highly recurrent and chronic depression, there was no apparent benefit to continuing the citalopram and augmenting with CT vs. switching to CT in terms of acute phase treatment features and outcomes, or probability of relapse over one year. Implications for clinical practice are discussed.
AB - Objective: This report compares the effectiveness of cognitive therapy (CT) as an augmentation to citalopram vs. CT as a switch from citalopram as a second-step treatment for outpatients with non-psychotic major depressive disorder (MDD) who had received unsatisfactory benefit from an initial trial of citalopram. Methods: Participants who experienced intolerance to or who did not reach remission with an optimal trial of citalopram, and who accepted randomization only to one of the two CT options, were randomized to a second-step treatment of either CT switch or CT augmentation of citalopram. Treatment outcomes, side effects, and serious adverse events were compared between the two groups. Results: As a second-step treatment following an optimal trial of citalopram, discontinuing medication and switching to CT (n=32) was as effective as augmenting citalopram with CT (n=26). Unlike the CT switch subjects, most individuals in the CT augmentation group endorsed mild-to-marked levels of side effect frequency, intensity, and burden. Conclusions: This is the first study to compare CT as a switch or augmentation strategy following unsatisfactory benefit or intolerance to an SSRI antidepressant medication. In these individuals with highly recurrent and chronic depression, there was no apparent benefit to continuing the citalopram and augmenting with CT vs. switching to CT in terms of acute phase treatment features and outcomes, or probability of relapse over one year. Implications for clinical practice are discussed.
UR - http://www.scopus.com/inward/record.url?scp=84887504791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887504791&partnerID=8YFLogxK
U2 - 10.1521/ijct.2009.2.1.66
DO - 10.1521/ijct.2009.2.1.66
M3 - Article
AN - SCOPUS:84887504791
SN - 1937-1209
VL - 2
SP - 66
EP - 87
JO - International Journal of Cognitive Therapy
JF - International Journal of Cognitive Therapy
IS - 1
ER -